Article
Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
Oncotarget - 19 Apr 2016
Lasorsa Vito Alessandro, Formicola Daniela, Pignataro Piero, Cimmino Flora, Calabrese Francesco Maria, Mora Jaume, Esposito Maria Rosaria, Pantile Marcella, Zanon Carlo, De Mariano Marilena, Longo Luca, Hogarty Michael D, de Torres Carmen, Tonini Gian Paolo, Iolascon Achille, Capasso Mario
Abstract excerpt
The spectrum of somatic mutation of the most aggressive forms of neuroblastoma is not completely determined. We sought to identify potential cancer drivers in clinically aggressive neuroblastoma.Whole exome sequencing was conducted on 17 germline and tumor DNA samples from high-risk patients with adverse events within 36 months from diagnosis (HR-Event3) to identify somatic mutations and deep targeted sequencing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.